NRx Pharmaceuticals Stock Forecast

NRXP's stock price has decreased by -55.58% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts with 12-month price forecasts for NRx Pharmaceuticals stock have an average target of 28.25, with a low estimate of 18 and a high estimate of 45. The average target predicts an increase of 1,379.06% from the current stock price of 1.91.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18	$28.25	$31	$45
Change	+842.41%	+1379.1%	+1523.0%	+2256.0%

Analyst Ratings

The average analyst rating for NRx Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	3	3	3	3	3	4
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Thomas Schrader BTIG	BTIG	Strong Buy Initiates $18	Strong Buy	Initiates	$18	+842.41%	Apr 2, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $31	Strong Buy	Maintains	$31	+1,523.04%	Mar 31, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $31	Strong Buy	Maintains	$31	+1,523.04%	Mar 24, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $31	Strong Buy	Maintains	$31	+1,523.04%	Mar 20, 2025
Vernon Bernardino HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $19	Strong Buy	Reiterates	$19	+894.76%	Mar 20, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 1.20B

Revenue Next Year

n/a

EPS This Year

-0.06

from -2.36

EPS Next Year

1.57

from -0.06

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	34.78M	113.57M	296.73M	592.45M	1.20B
Revenue Growth	-	226.52%	161.27%	99.66%	102.72%	-	-	-
EPS	-15.11	-74.40	-6.04	-3.98	-2.36	-0.06	1.57	5.03
EPS Growth	-	-	-	-	-	-	-	220.13%
Forward PE	-	-	-	-	-	-	1.22	0.38
No. Analysts	-	-	-	-	-	5	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	40.1M	189.3M	544.6M
Avg	34.8M	113.6M	296.7M
Low	29.4M	41.6M	61.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-96.7%	444.2%	379.5%
Avg	-97.1%	226.5%	161.3%
Low	-97.6%	19.5%	-45.5%

EPS Forecast

EPS	2025	2026	2027
High	-0.06	1.62	5.18
Avg	-0.06	1.57	5.03
Low	-0.06	1.51	4.83

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	229.5%
Avg	-	-	220.1%
Low	-	-	207.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.